Onkos Surgical, a leading provider of innovative solutions for complex orthopaedic procedures headquartered in Parsippany, has opened the NanoCept Innovation Center in Bridgewater Township after a ribbon-cutting ceremony on Dec. 9.
Located in the New Jersey Center of Excellence campus, the new 4,600-square-foot facility will allow the company to bring a full innovation process in-house for its flagship NanoCept antibacterial technology, the first-ever orthopaedic antibacterial coating commercially available on the U.S. market.
The product offers a proactive approach against intraoperative bacterial contamination, a crucial advancement in the field of orthopaedic implants. The production capacity expansion will allow the company to meet a growing demand for the NanoCept technology from surgeons and hospitals.
“Onkos is proud to have worked with the FDA to bring to market the first antibacterial coating technology. The opening of the NanoCept Innovation Center marks another important milestone in our company’s journey,” said Patrick Treacy, founder and CEO.
“This investment will allow us to get this groundbreaking technology into the hands of more surgeons, faster, and it puts us in a position to help more patients with complex orthopaedic conditions.”
“I am excited by Onkos’ commitment to bring this technology to more implants and ultimately to more patients,” said Steven Gitelis, M.D., director of Rush University/MD Anderson’s Orthopaedic Oncology Program and chief medical officer of Onkos.
“This is a unique technology that arms us, as surgeons, with a powerful solution to help mitigate the serious issue of bacteria in the operating room.”
The NanoCept Innovation Center will employ a team of chemists, engineers and technicians in the new facility to lead its innovation operations. These include using the latest innovations in antibacterial implant coatings, virtual surgical planning, 3D anatomic modeling and printing, implant design and workflow optimization.
